Family Communication of Hereditary Breast and Ovarian Cancer Risk Among African Americans
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01374685|
Recruitment Status : Terminated
First Posted : June 16, 2011
Last Update Posted : July 18, 2019
- Certain genetic mutations are linked to higher rates of cancer. It is important for people with these mutations to tell their families about it. This is because others in the family may also be at greater risk for developing these cancers. They can also pass these genes to their own children. But not much is known about how African Americans tell their family members about the results of their genetic testing. The information from this study can be used to improve genetic counseling services. These services will then be more effective in early cancer detection and prevention in the African American community.
- To learn more about how African Americans who have tested positive for BRCA1/2 mutations tell their families about their genetic risk.
- African American (or of African descent) women who recently received positive test results for BRCA1/2 mutations.
- Participants will be screened with a basic medical history.
- They will be asked general questions about their personal and family history. These include questions on marital and health insurance status, education, and income.
- Those in the study will have a 45- to 60-minute phone interview. They will answer questions about how they told their family members about their genetic test results. They will also be asked what that experience was like.
|Condition or disease|
|Ovarian Neoplasm Cancer Genetics Breast Cancer|
|Study Type :||Observational|
|Actual Enrollment :||8 participants|
|Official Title:||Family Communication of Hereditary Cancer Risk Among African Americans|
|Study Start Date :||June 7, 2011|
|Study Completion Date :||January 7, 2016|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01374685
|United States, Maryland|
|National Human Genome Research Institute (NHGRI), 9000 Rockville Pike|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||Barbara B Biesecker||National Human Genome Research Institute (NHGRI)|